| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Nafronyl Oxalate targets vascular smooth muscle and serotonin receptors. It acts as a vasodilator that works by increasing blood flow to the brain and other parts of the body. The compound enhances cellular oxidative capacity and may also act as an antagonist at 5-HT2 serotonin receptors. It is claimed to be a spasmolytic. The compound's vasodilatory effects improve peripheral and cerebral circulation, making it useful for vascular disorders.
|
|---|---|
| ln Vitro |
Naphthofuryl oxalate, also known as furyl oxalic acid, is useful in treating muscle spasm discomfort [1]. The only vasoactive medication that may be used affordably to treat peripheral arterial disease (PAD) is fumarate (naphthofuryl oxalate) [2]. Phenothofuryl oxalate, also known as fury oxalate, was found to be the most effective drug in terms of maximum walking distance (MWD) and pain-free walking distance (PFWD) (probability of optimal treatment: 0.987 and 0.987, respectively). Cilostazol and pentoxifylline were the next in line. For claudication, furyl oxalates, or naphthyl oxalate, are useful therapies. Of them, naphfuryl oxalate is perhaps the most beneficial because it has the fewest major side effects [3].
In vitro, Nafronyl Oxalate enhances cellular oxidative capacity. It may also act as an antagonist at 5-HT2 serotonin receptors. The compound's vasodilatory activity has been characterized in vascular tissue studies. It is used as a reference compound in peripheral arterial disease research. Detailed in vitro data are available in the primary literature. The compound is a well-characterized vasoactive agent. |
| ln Vivo |
In vivo, Nafronyl Oxalate is used clinically for the management of peripheral and cerebral vascular disorders. It acts as a vasodilator, increasing blood flow to the brain and peripheral tissues. The compound has been used for the treatment of cerebral insufficiency, peripheral vascular disease, and vertigo. It is the only vasoactive drug for PAD likely to be cost-effective. Nafronyl Oxalate is a well-established pharmaceutical agent in some countries.
|
| Enzyme Assay |
In vitro vasodilatory assays for Nafronyl Oxalate typically use isolated vascular tissue (e.g., rat aorta) or vascular smooth muscle cells. The compound is dissolved in DMSO or appropriate solvent and diluted in physiological buffer. Vascular rings are pre-contracted with vasoconstrictors (e.g., phenylephrine), and relaxation responses to increasing concentrations of Nafronyl Oxalate are measured. IC₅₀ values for vasodilation are calculated. 5-HT2 receptor antagonism is assessed in serotonin-induced contraction assays. Controls include vehicle and known vasodilators.
|
| Cell Assay |
For cell-based assays, vascular smooth muscle cells or endothelial cells are cultured in appropriate medium. Cells are seeded in multi-well plates and treated with Nafronyl Oxalate at various concentrations for 24-72 hours. Cellular oxidative capacity is assessed by measuring ATP levels or mitochondrial function. Cell viability is assessed by MTT or CellTiter-Glo. Calcium signaling may be measured in response to vasoactive stimuli. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Nafronyl Oxalate is typically administered orally to patients. For animal studies, rodents are dosed orally or via other routes. Peripheral and cerebral blood flow is measured using laser Doppler flowmetry or other techniques. For vascular disorder models, animals are treated with Nafronyl Oxalate at various regimens. Endpoints include blood flow improvement, functional recovery, and tissue histology. Blood samples are collected for pharmacokinetic analysis. All procedures follow institutional guidelines.
|
| ADME/Pharmacokinetics |
Nafronyl Oxalate (Naftidrofuryl oxalate, MW 473.56, C₂₄H₃₃NO₆) is a vasodilator used for peripheral and cerebral vascular disorders. The compound is typically administered orally. Detailed pharmacokinetic parameters (bioavailability, half-life, clearance) are available from pharmacological literature. The compound is metabolized in the liver. It is a well-characterized pharmaceutical agent available in several countries.
|
| Toxicity/Toxicokinetics |
Nafronyl Oxalate is a clinically used drug with an established safety profile. It is used for the management of peripheral arterial disease and cerebral vascular insufficiency. Common side effects include gastrointestinal disturbances. The compound is contraindicated in patients with hypersensitivity. It is available as a pharmaceutical product in several countries. Standard precautions for vasodilator use apply.
|
| References |
|
| Additional Infomation |
A drug used to treat peripheral and cerebrovascular diseases. It is said to enhance cellular oxidation capacity and has antispasmodic effects. (From Martindale Pharmacopoeia, 30th edition, p. 1310) It may also be a serotonin 2 receptor antagonist.
Nafronyl Oxalate (Naftidrofuryl oxalate) is a clinically used vasodilator for peripheral and cerebral vascular disorders. It enhances cellular oxidative capacity and may also act as a 5-HT2 receptor antagonist. The compound is the only vasoactive drug for PAD likely to be cost-effective. It is available as a pharmaceutical product and from chemical suppliers for research purposes. Its mechanism involves vasodilation and improved blood flow. |
| Molecular Formula |
C26H35NO7
|
|---|---|
| Molecular Weight |
473.57
|
| Exact Mass |
473.241
|
| CAS # |
3200-06-4
|
| PubChem CID |
312915
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2205 (rough estimate)
|
| Boiling Point |
574°C (rough estimate)
|
| Melting Point |
110-111°
|
| Index of Refraction |
1.6000 (estimate)
|
| LogP |
3.608
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
34
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SSAJNPNVUYMUCI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H33NO3.C2H2O4/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20;3-1(4)2(5)6/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3;(H,3,4)(H,5,6)
|
| Chemical Name |
2-(diethylamino)ethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate;oxalic acid
|
| Synonyms |
Naphtidrofuryl oxalate; Naftidrofuryl oxalate; Nafronyl Oxalate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~211.17 mM)
H2O : ~100 mg/mL (~211.17 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 50 mg/mL (105.58 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1116 mL | 10.5581 mL | 21.1162 mL | |
| 5 mM | 0.4223 mL | 2.1116 mL | 4.2232 mL | |
| 10 mM | 0.2112 mL | 1.0558 mL | 2.1116 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
